Skip to content
superstack
Draft entry. Written from the cited papers but not yet reviewed by a person. Check the references before relying on any claim.

Mitochonic Acid 5

also MA-5 · Mitochonic acid-5 · Mitochonic-Acid 5

Mitochonic Acid 5 (MA-5) is a synthetic indole compound studied for mitochondrial disease. It binds mitofilin/MIC60, a protein involved in organizing the inner mitochondrial membrane [1]. Human development has reached phase I safety testing; clinical benefit remains unproven [2].

MA-5 has early human safety data and extensive laboratory research. Clinical benefit remains unproven, and some preclinical models showed dose-dependent harm.

2D chemical structure of Mitochonic Acid 5
C18H13F2NO3329.3 g/molCID 76070959 ↗
Early human trials11 papers · 2015–2026 · 11 journals · 1 in humans
  • meta-analysis
  • RCT
  • trial
  • observational
  • preclinical / case
  • review / patent / other
  • retracted
2015 · preclinical · Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases.2016 · preclinical · Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage.2017 · preclinical · Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases.2024 · other · Physician-Initiated Phase I Study of MA-5 for the Treatment of Mitochondrial Disease -A Phase I Study of MA-5 for the Treatment of Mitochondrial Disease in Healthy Adults2025 · preclinical · Mitochondria-Homing Drug Mitochonic Acid 5 Improves Barth Syndrome Myopathy in a Human-Induced Pluripotent Stem Cell Model and Barth Syndrome Drosophila Model.2025 · preclinical · Non-DNA-damaging DNA-PK activation improving hearing and prolonging life due to NAD+ and SIRT upregulation2025 · other · Investigator-Initiated Phase II Clinical Trial of MA-5 for Mitochondrial Disease An Exploratory, Investigator-Initiated Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MA-5 in Patients with Mitochondrial Disease and Hearing Loss2025 · preclinical · Mitochonic acid 5 mitigates age-related hearing loss progression by targeting defective 2-methylthiolation in mitochondrial transfer RNAs.2026 · preclinical · Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset.2026 · preclinical · Mitochonic acid 5 alleviates amyotrophic lateral sclerosis phenotypes via mitochondrial augmentation.2026 · preclinical · Therapeutic potential of mitochonic acid (MA-5) in modulating mitochondrial function and inflammatory responses: A focus on carnitine/acylcarnitine carrier (SLC25A20) transport activity.
in its favor
  • + Improved ATP production and survival in mitochondrial disease cells
  • + Reduced kidney injury in mouse models
  • + Completed a short phase I safety study
watch for
  • − Human efficacy remains unproven
  • − Higher doses damaged cochlear cells in a mouse study
  • − Long-term human safety is unresolved

Researchers identified MA-5 by screening indole-3-acetic-acid derivatives for compounds that increased cellular ATP. The 2015 discovery study tested cells from patients with Leigh syndrome, MELAS, Leber hereditary optic neuropathy and Kearns–Sayre syndrome [3].

In a 2017 study, MA-5 protected fibroblasts from 24 of 25 patients against experimentally induced oxidative stress. The remaining cell line resisted the stressor itself, so the assay could not assess whether MA-5 helped it. All treatment took place in cultured cells [4].

Animal and disease-model findings

  • In a 2026 study of mitochondrial DNA deletion disease, seven symptomatic mice received MA-5 and seven received vehicle. MA-5 lowered creatinine and improved kidney tissue structure. Resting lactate did not differ significantly between the disease groups, although lactate improved after glucose loading. Cardiac respiratory histochemistry also found no significant difference between the groups [5].
  • A 2025 Barth syndrome study found that MA-5 improved ATP production and mitochondrial morphology in patient-derived cells, and movement and heart rate in flies. It left the abnormal monolysocardiolipin/cardiolipin ratio unchanged [6].
  • A September 2026 ALS study found better movement and survival in flies and increased ATP production in patient-derived motor neurons. The exploratory mouse experiment had only one animal per group, precluding statistical inference [7].

Hearing and survival findings from a 2025 preprint

Honkura and colleagues reported better auditory brainstem response thresholds and preservation of cochlear tissue in Ndufs4-knockout mice, a model of Leigh syndrome. They also found benefits in models of hearing injury caused by noise or cisplatin. In the knockout mice, treatment started after hearing decline still helped at selected frequencies. The noise experiment tested treatment begun before exposure; whether MA-5 helps when started after noise injury remains unanswered. Hearing groups were small, generally five or six animals [8].

Oral MA-5 prolonged survival in Ndufs4-knockout mice (reported p < 0.05). The mice had severe mitochondrial disease; healthy-aging lifespan effects were not tested. Gene-expression profiles overlapped with some cellular reprogramming signatures and opposed some aging signatures. Those comparisons do not show that MA-5 causes rejuvenation or extends human lifespan. These findings come from a preprint that has not been peer reviewed [8].

Clinical development

Phase I safety testing is complete. Clinical benefit remains unproven [2]. The phase II trial jRCT2031250505 targets 15 people with mitochondrial disease and hearing loss. As checked on October 30, 2026, the registry lists it as not recruiting, with no posted efficacy results. The blinded, placebo-controlled protocol lasts 12 weeks and measures hearing, disease markers and safety [9].

Mitofilin/MIC60 helps organize cristae, the folds of the inner mitochondrial membrane. Affinity purification and binding assays supported MA-5 binding to this protein, though affinity estimates varied by assay. Human target engagement has not been established [1].

In the 2017 experiments, MA-5 promoted ATP synthase oligomerization, the assembly of individual enzymes into larger complexes. The proposed mechanism is that changes in local membrane organization make ATP production more efficient. ATP increased in the tested fibroblasts while oxygen consumption and the membrane potential of the mitochondria as a whole stayed unchanged [4].

Its effects on oxidative stress vary by model. In the discovery study, MA-5 neither reduced cellular ROS during peroxide stress nor replenished glutathione. A general ability to scavenge free radicals directly has not been established [3].

A 2026 biochemical study found that MA-5 reversibly inhibited the carnitine/acylcarnitine carrier through non-competitive inhibition. Reported IC50 values were approximately 73 µM for native rat protein and 58 µM for recombinant protein. The study used isolated transport assays; it established neither clinical fat loss nor a drug interaction [10].

Proposed NAD+ and sirtuin mechanisms (preprint)

The 2025 preprint proposes an additional mechanism involving the NAD+ salvage pathway. The S-enantiomer increased NAMPT activity and cellular NAD+. The R-enantiomer and racemic MA-5 had weaker or less consistent effects. Binding assays gave a NAMPT dissociation constant of about 59 µM for the S-enantiomer and 106 µM for the racemate; no R-enantiomer binding was detectable in that assay. These binding estimates are in the micromolar range, while the activity assays used nanomolar concentrations, so the two measures cannot be used interchangeably as potency estimates. NMNAT1 and NMNAT3 activity did not increase [8].

The S-enantiomer also increased SIRT1–7 protein levels in the tested cells without increasing their mRNA. The authors propose that it slows protein degradation. They observed increased DNA-PKcs phosphorylation at Ser2056 and TRIM28 phosphorylation at Ser824, alongside reduced K48-linked SIRT1 polyubiquitination. Knocking down DNA-PKcs prevented the TRIM28 phosphorylation response. Direct binding of the S-enantiomer to DNA-PK remains a computational prediction, with no binding assay to confirm it [8].

SIRT1 activity increased in extracts from treated cells. Isolated SIRT1 and PARP1 enzyme assays, however, showed no direct activation. The authors propose that greater NAD+ availability and sirtuin protein abundance explain the cellular effects. This mechanism has been studied in cells and biochemical assays, with no confirmation in treated humans [8].

Direct targetswhat the molecule itself binds or acts on
  • Mitofilin / MIC60 (IMMT)modulates
    Biochemical assays demonstrated binding to mitofilin/MIC60, which may help organize mitochondrial cristae [1].
    moderate
  • Carnitine/acylcarnitine carrier (SLC25A20)blocks
    MA-5 inhibited transport in reconstituted protein assays. Whether this occurs at human exposure levels is unknown [10].
    moderate
  • Nicotinamide phosphoribosyltransferase (NAMPT)activates
    In a 2025 preprint, the S-enantiomer bound recombinant NAMPT and increased its activity. The preprint provides no evidence of target engagement in humans [8].
    weak
Downstreamconsequences of that action, not targets of their own
  • ATP synthase oligomerizationmodulates
    MA-5 promoted the formation of ATP synthase dimers and larger complexes in laboratory experiments [4].
    moderate
  • DNA-PK / TRIM28 / sirtuin signalingmodulates
    The S-enantiomer increased DNA-PKcs and TRIM28 phosphorylation and sirtuin protein levels in cell experiments. Direct binding to DNA-PK remains a docking prediction [8].
    weak

Formulation

how the form changes blood levels

MA-5 is a racemic mixture with equal amounts of its R- and S-enantiomers. In the 2025 preprint, both increased ATP and protected stressed MELAS fibroblasts. The S-enantiomer had stronger effects on several NAD+/sirtuin measures. The animal hearing and survival experiments used racemic MA-5, so they cannot establish whether isolated S-MA-5 works better in animals or people [8].

The authors gave each enantiomer separately to a male rhesus monkey at 1 mg/kg intravenously. They detected no conversion between the enantiomers in plasma samples taken from five minutes to 24 hours afterward. The experiment provides no human enantiomer pharmacokinetic data [8].

Dosing

as studied or commonly reported; not a recommendation

Doses below are what studies used or, where marked, what is commonly reported. None is a recommendation.

Oral

  • 5 mg or 10 mg (single-capsule cohorts)
    Healthy men; phase I registry protocol
    single fasting dose · one dose
    human study[2]
  • 10 mg (one-capsule cohort)
    Healthy men; phase I registry protocol
    repeated fasting administration · 7 days
    human study[2]
  • 50 mg/kg
    Mice with symptomatic mitochondrial DNA deletion disease; seven treated and seven disease controls
    once daily by gavage · 27 days
    animal study[5]
  • 2 or 4 mg/kg/day
    Female Cdk5rap1-knockout mice with early hearing loss; the higher dose increased outer hair-cell loss
    in drinking water · 8 weeks
    animal study[11]
  • 10 mg/kg
    Ndufs4-knockout mice; survival experiment in a 2025 preprint
    continued until end of life
    animal study[8]
Time to effect
Researchers measured increased ATP after three hours in cultured mitochondrial disease fibroblasts. This cell-assay endpoint does not establish a human onset of benefit [4].
Notes
The phase I registry also lists two- and four-capsule cohorts, but its English dose wording is ambiguous. The table includes only clearly stated phase I doses. The registry is not peer reviewed [2]. The 2025 preprint reports oral 10 mg/kg for the mouse survival experiment without specifying how often it was given. For some hearing and cochlear experiments, the text and figure legends disagree on whether doses were in µg/kg or mg/kg. Those protocols remain uncertain [8].

Pharmacokinetics

what the body does with it
Half-lifeNot quantified in the public phase I results [2].
Time to peakAbout 1 hour in mice after oral doses of 25, 50 or 150 mg/kg. The study provides no human estimate [1].
BioavailabilityMouse studies demonstrated oral absorption but reported no absolute bioavailability percentage [1]. A 2025 preprint detected MA-5 in mouse cochlear tissue one hour after oral administration, showing that it reached the inner ear in mice [8].
Steady statePhase I reported linear exposure and unchanged PK after seven days. It did not report when steady state was reached [2].

Safety

risks and cautions, not medical advice

The phase I registry reports grade 1 adverse events in seven of 58 healthy men, including placebo recipients. It reports no reactions attributed to MA-5, serious events or discontinuations, but does not disclose the event types. Long-term safety remains unresolved [2].

The 2025 hearing-loss mouse study found a dose-dependent adverse signal. Several hearing measures improved at 2 mg/kg/day. At 4 mg/kg/day, outer hair-cell loss increased and otoacoustic emissions worsened at some frequencies. The small study cannot define a human toxicity threshold [11].

The 2026 ALS paper also found that benefits depended on concentration. In motor neurons, 100 nM improved ATP, while 10 µM or more appeared ineffective or potentially harmful. Sporadic-ALS fibroblasts showed less benefit or possible harm at 30 µM [7].

In the 2025 preprint, the S-enantiomer reduced the DNA-damage marker γH2AX in auditory cells exposed to doxorubicin or camptothecin. The authors also report negative Ames and micronucleus tests during development, without providing detailed results. These experiments leave long-term human safety and the safety of combining MA-5 with chemotherapy unresolved [8].

Adverse effects
reported, not universal
  • Increased outer hair-cell loss at 4 mg/kg/day in the hearing-loss mouse model [11].
  • Possible cellular harm at higher concentrations in the ALS experiments [7].
Cautions
who should think twice
  • Preclinical benefits were not consistently greater at higher doses [7][11].
Limits of the evidence
what has not been shown
  • Human symptom improvement remains unproven despite the cell rescue, ATP changes and animal outcomes [3][6][7].
  • The early mouse lifespan experiment had just one control and two treated mice, too few for a survival analysis [1].
  • The small 2026 mitochondrial disease experiment showed clearer benefits in the kidneys than in the heart [5].
  • The 2025 NAD+/DNA-PK preprint has not been peer reviewed. Its text and figures contain conflicting dose units and other inconsistencies, and its survival analysis does not clearly report group sizes or median survival. Its mechanistic findings leave human anti-aging effects unproven [8].

Interactions

documented pairs only, not exhaustive

The cited studies have not established the safety of combining MA-5 with other compounds. Carrier inhibition was measured in biochemical assays. No clinical interaction with carnitine supplements was demonstrated [10].

Is MA-5 a peptide?
No. It is a synthetic indole small molecule derived from indole-3-acetic acid [3].
Does MA-5 repair mitochondrial DNA?
The mouse study found tissue improvements while the burden of deleted mitochondrial DNA stayed high. Genetic correction was not demonstrated [5].
Has MA-5 been shown to treat ALS?
No people with ALS were treated in the cited study. It tested flies, cultured patient-derived cells and one mouse per group in an exploratory comparison [7].

References

entry last reviewed 2026-10-01
  1. [1]
    Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage.
    Suzuki T, Yamaguchi H, Kikusato M et al.J Am Soc Nephrol 2016preclinical · animalPMID 26609120◌ unreviewed
  2. [2]
  3. [3]
    Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases.
    Suzuki T, Yamaguchi H, Kikusato M et al.Tohoku J Exp Med 2015preclinical · cellPMID 26118651◌ unreviewed
  4. [4]
    Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases.
    Matsuhashi T, Sato T, Kanno SI et al.EBioMedicine 2017preclinical · animalPMID 28579242◌ unreviewed
  5. [5]
    Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset.
    Ogasawara E, Tani H, Suzuki C et al.Sci Rep 2026preclinical · animalPMID 42270754◌ unreviewed
  6. [6]
  7. [7]
    Mitochonic acid 5 alleviates amyotrophic lateral sclerosis phenotypes via mitochondrial augmentation.
    Oikawa Y, Luo Y, Suzuki N et al.JCI Insight 2026preclinical · animalPMID 42770300◌ unreviewed
  8. [8]
    Non-DNA-damaging DNA-PK activation improving hearing and prolonging life due to NAD+ and SIRT upregulation
    Honkura, Y., Suzuki, T., Kujirai, R. et al.bioRxiv (preprint) 2025preclinical · animal◌ unreviewed
  9. [9]
  10. [10]
  11. [11]
    Mitochonic acid 5 mitigates age-related hearing loss progression by targeting defective 2-methylthiolation in mitochondrial transfer RNAs.
    Kouga T, Miwa T, Wei FY et al.Front Cell Neurosci 2025preclinical · animalPMID 40260078◌ unreviewed